What is HC Wainwright’s Estimate for ESPR FY2028 Earnings?

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Stock analysts at HC Wainwright cut their FY2028 EPS estimates for Esperion Therapeutics in a report released on Thursday, January 23rd. HC Wainwright analyst J. Pantginis now anticipates that the biopharmaceutical company will earn $0.16 per share for the year, down from their previous estimate of $6.05. HC Wainwright currently has a “Buy” rating and a $16.00 target price on the stock. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.28) per share.

A number of other equities research analysts also recently issued reports on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $6.00 price objective on shares of Esperion Therapeutics in a research report on Friday, December 13th. JMP Securities reissued a “market outperform” rating and set a $7.00 target price on shares of Esperion Therapeutics in a research report on Thursday. The Goldman Sachs Group started coverage on shares of Esperion Therapeutics in a research report on Wednesday, December 18th. They set a “neutral” rating and a $4.00 target price for the company. Cantor Fitzgerald started coverage on shares of Esperion Therapeutics in a research report on Tuesday, December 17th. They set an “overweight” rating and a $8.00 target price for the company. Finally, StockNews.com downgraded shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $7.25.

Esperion Therapeutics Price Performance

ESPR opened at $2.10 on Monday. Esperion Therapeutics has a fifty-two week low of $1.58 and a fifty-two week high of $3.94. The firm has a market capitalization of $413.78 million, a PE ratio of -3.28 and a beta of 1.03. The company’s 50-day moving average is $2.46 and its 200 day moving average is $2.17.

Esperion Therapeutics (NASDAQ:ESPR) last posted its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). The company had revenue of $51.63 million for the quarter, compared to the consensus estimate of $55.44 million. During the same quarter in the previous year, the company earned ($0.37) EPS.

Institutional Trading of Esperion Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in ESPR. American Century Companies Inc. purchased a new stake in shares of Esperion Therapeutics during the 2nd quarter valued at $50,000. Xponance Inc. bought a new stake in Esperion Therapeutics in the 2nd quarter worth $28,000. Marshall Wace LLP grew its holdings in Esperion Therapeutics by 94.2% in the 2nd quarter. Marshall Wace LLP now owns 4,303,596 shares of the biopharmaceutical company’s stock worth $9,554,000 after acquiring an additional 2,087,635 shares during the last quarter. Deerfield Management Company L.P. Series C bought a new stake in Esperion Therapeutics in the 2nd quarter worth $148,000. Finally, The Manufacturers Life Insurance Company bought a new stake in Esperion Therapeutics in the 2nd quarter worth $159,000. Hedge funds and other institutional investors own 47.39% of the company’s stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.